Literature DB >> 24976913

Clinical disease registries in acute myocardial infarction.

Reza Ashrafi1, Hussain Hussain1, Robert Brisk1, Leanne Boardman1, Clive Weston1.   

Abstract

Disease registries, containing systematic records of cases, have for nearly 100 years been valuable in exploring and understanding various aspects of cardiology. This is particularly true for myocardial infarction, where such registries have provided both epidemiological and clinical information that was not readily available from randomised controlled trials in highly-selected populations. Registries, whether mandated or voluntary, prospective or retrospective in their analysis, have at their core a common study population and common data definitions. In this review we highlight how registries have diversified to offer information on epidemiology, risk modelling, quality assurance/improvement and original research-through data mining, transnational comparisons and the facilitation of enrolment in, and follow-up during registry-based randomised clinical trials.

Entities:  

Keywords:  Acute coronary syndrome; Audit; Coronary artery disease; Ethics; Health statistics; Myocardial infarction; Patient records; Patient safety; Research

Year:  2014        PMID: 24976913      PMCID: PMC4072831          DOI: 10.4330/wjc.v6.i6.415

Source DB:  PubMed          Journal:  World J Cardiol


  60 in total

1.  Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group.

Authors:  R M Norris
Journal:  BMJ       Date:  1998-04-04

2.  Tower Hamlets coronary project.

Authors:  H D Pedoe
Journal:  Br J Prev Soc Med       Date:  1972-02

3.  Harvesting knowledge from improvement.

Authors:  D M Berwick
Journal:  JAMA       Date:  1996-03-20       Impact factor: 56.272

4.  Uses of coronary heart attack registers.

Authors:  H T Pedoe
Journal:  Br Heart J       Date:  1978-05

5.  Impact of missing data on standardised mortality ratios for acute myocardial infarction: evidence from the Myocardial Ischaemia National Audit Project (MINAP) 2004-7.

Authors:  C P Gale; B A Cattle; J Moore; H Dawe; D C Greenwood; R M West
Journal:  Heart       Date:  2011-01-12       Impact factor: 5.994

6.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

7.  Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.

Authors:  Tomas Jernberg; Per Johanson; Claes Held; Bodil Svennblad; Johan Lindbäck; Lars Wallentin
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

8.  Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database.

Authors:  C P Gale; S O M Manda; P D Batin; C F Weston; J S Birkhead; A S Hall
Journal:  Heart       Date:  2007-12-10       Impact factor: 5.994

9.  Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study.

Authors:  Birgit Frilling; Rudolf Schiele; Anselm Kai Gitt; Ralf Zahn; Steffen Schneider; Hans-Georg Glunz; Ulf Gieseler; Edwin Jagodzinski; Jochen Senges
Journal:  Am Heart J       Date:  2004-08       Impact factor: 4.749

10.  The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART).

Authors:  Tomas Jernberg; Mona F Attebring; Kristina Hambraeus; Torbjorn Ivert; Stefan James; Anders Jeppsson; Bo Lagerqvist; Bertil Lindahl; Ulf Stenestrand; Lars Wallentin
Journal:  Heart       Date:  2010-08-27       Impact factor: 5.994

View more
  1 in total

Review 1.  Defining key design elements of registry-based randomised controlled trials: a scoping review.

Authors:  Bill Karanatsios; Khic-Houy Prang; Ebony Verbunt; Justin M Yeung; Margaret Kelaher; Peter Gibbs
Journal:  Trials       Date:  2020-06-22       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.